用于肺癌的 NIR-II 五模式成像引导协同光热疗法和 CAR-NK 免疫疗法的温度反馈纳米平台,Small

当前位置： X-MOL 学术 › Small › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

用于肺癌的 NIR-II 五模式成像引导协同光热疗法和 CAR-NK 免疫疗法的温度反馈纳米平台
Small ( IF 13.0 ) Pub Date : 2021-06-23 , DOI: 10.1002/smll.202101397
Mengze Xu _{1,

2,

3} , Bin Xue _{1,

4} , Yue Wang ₁ , Dan Wang ₁ , Duyang Gao ₁ , Shuo Yang ₁ , Qi Zhao ₁ , Cangtao Zhou ₄ , Shuangchen Ruan ₄ , Zhen Yuan _{1,

2,

3}

Affiliation

在这项研究中，为了在进行协同光热疗法 (PTT) 和肿瘤靶向免疫疗法的同时，直观地获取肺癌的全方位结构和功能信息，一种将上转换纳米粒子 (UCNPs) 和 IR-1048 染料引入脂质的治疗诊断纳米平台 -构建适体纳米结构（UCILA）。有趣的是，嫁接到脂双层中的 IR-1048 染料可以作为光声成像、光学相干断层扫描血管造影、光热成像和第二个近红外 (NIR-II) 窗口中的 PTT 的治疗诊断剂。此外，装载在UCILA内部的UCNPs具有优越的发光特性和高X射线衰减系数，可作为计算机断层扫描（CT）和热敏上转换发光（UCL）成像的造影剂，能够实时跟踪肿瘤的代谢活动和温度反馈 PTT。此外，在五模态成像和PTT过程中原位温度变化的准确监测的互补指导下，UCILA在消融肺肿瘤方面表现出优异的能力，并且副作用最小。同时，协同CAR-NK免疫疗法专门用于根除PTT后任何可能的残留肿瘤细胞。因此，UCILA 纳米平台被证明是一种多功能的治疗诊断剂，可用于五模式成像和温度反馈 PTT，同时进行肺癌靶向免疫治疗。在五模态成像和PTT过程中原位温度变化的准确监测的互补指导下，UCILA在消融肺肿瘤方面表现出优异的能力，并且副作用最小。同时，协同CAR-NK免疫疗法专门用于根除PTT后任何可能的残留肿瘤细胞。因此，UCILA 纳米平台被证明是一种多功能的治疗诊断剂，可用于五模式成像和温度反馈 PTT，同时进行肺癌靶向免疫治疗。在五模态成像和PTT过程中原位温度变化的准确监测的互补指导下，UCILA在消融肺肿瘤方面表现出优异的能力，并且副作用最小。同时，协同CAR-NK免疫疗法专门用于根除PTT后任何可能的残留肿瘤细胞。因此，UCILA 纳米平台被证明是一种多功能的治疗诊断剂，可用于五模式成像和温度反馈 PTT，同时进行肺癌靶向免疫治疗。

"点击查看英文标题和摘要"

Temperature-Feedback Nanoplatform for NIR-II Penta-Modal Imaging-Guided Synergistic Photothermal Therapy and CAR-NK Immunotherapy of Lung Cancer

In this study, to visually acquire all-round structural and functional information of lung cancer while performing synergistic photothermal therapy (PTT) and tumor-targeting immunotherapy, a theranostic nanoplatform that introduced upconversion nanoparticles (UCNPs) and IR-1048 dye into the lipid-aptamer nanostructrure (UCILA) is constructed. Interestingly, the IR-1048 dye grafted into the lipid bilayer can serve as the theranostic agent for photoacoustic imaging, optical coherence tomography angiography, photothermal imaging, and PTT in the second near infrared (NIR-II) window. In addition, loaded in the inner part of UCILA, UCNPs possess the superior luminescence property and high X-ray attenuation coefficient, which can act as contrast agents for computed tomography (CT) and thermo-sensitive up-conversion luminescence (UCL) imaging, enabling real-time tracking of metabolic activity of tumor and temperature-feedback PTT. Furthermore, under the complementary guidance of penta-modal imaging and an accurate monitoring of in situ temperature change during PTT, UCILA exhibits its excellent capability for ablating the lung tumor with minimal side effects. Meanwhile, synergistic CAR-NK immunotherapy is carried out specifically to eradicate any possible residual tumor cells after PTT. Therefore, the UCILA nanoplatform is demonstrated as a multifunctional theranostic agent for both penta-modal imaging and temperature-feedback PTT while conducting targeting immunotherapy of lung cancer.

更新日期：2021-06-23

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南